EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 (A4166) is a highly potent and selective inhibitor of the DOT1L histone methyltransferase enzyme, with an IC50 of 0.8 nM and a Ki of 80 pM under biochemical assay conditions (APExBIO). It is >37,000-fold more selective for DOT1L than other methyltransferases, including CARM1, EHMT1/2, and PRMTs. EPZ5676 competitively occupies the S-adenosyl methionine (SAM) binding pocket, inducing conformational changes that favor substrate selectivity. In vitro and in vivo studies demonstrate robust inhibition of H3K79 methylation and cytotoxicity in MLL-rearranged leukemia cell lines, with complete tumor regression observed in MV4-11 xenograft models at 35–70 mg/kg/day for 21 days (Ishiguro et al., 2025). EPZ5676 enhances the efficacy of immunomodulatory drugs in multiple myeloma models by reprogramming innate immune signaling.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is a histone methyltransferase responsible for methylating lysine 79 on histone H3 (H3K79). This post-translational modification is associated with transcriptional activation and elongation (Ishiguro et al., 2025). MLL-rearranged leukemias are characterized by aberrant recruitment of DOT1L to target genes, resulting in increased H3K79 methylation and overexpression of leukemogenic genes. Inhibition of DOT1L disrupts this epigenetic program, downregulating genes critical for leukemia cell survival such as HOXA9 and MEIS1. Genome-scale CRISPR studies confirm that MLL-rearranged leukemia and multiple myeloma cell lines are preferentially dependent on DOT1L for survival (Ishiguro et al., 2025). Thus, DOT1L is a validated therapeutic target in these malignancies, and EPZ5676 provides a selective tool for mechanistic and translational research.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a SAM-competitive inhibitor. It binds to the SAM pocket of DOT1L, blocking methyl group transfer to H3K79. Structural studies reveal that EPZ5676 induces conformational changes in DOT1L, opening a hydrophobic pocket beyond the SAM amino acid portion (APExBIO). This unique interaction confers high selectivity. The inhibitor displays an IC50 of 0.8 nM and a Ki of 80 pM in biochemical enzyme inhibition assays. Selectivity profiling shows >37,000-fold preference for DOT1L versus related methyltransferases (CARM1, EHMT1/2, EZH1/2, PRMT family, SETD7, SMYD2/3, WHSC1/1L1). In cellular models, EPZ5676 treatment leads to rapid loss of H3K79 methylation and downregulation of MLL-fusion target genes. This triggers cell cycle arrest and apoptosis in MLL-rearranged leukemia cells. In multiple myeloma models, DOT1L inhibition by EPZ5676 upregulates interferon-regulated genes (IRGs) and activates innate immune pathways, further enhancing antitumor effects (Ishiguro et al., 2025).

Evidence & Benchmarks

• EPZ5676 (A4166) exhibits an in vitro IC50 of 0.8 nM against DOT1L, with a Ki of 80 pM in enzymatic assays (APExBIO, product page).
• Demonstrates >37,000-fold selectivity for DOT1L over other methyltransferases including CARM1, EHMT1/2, PRMTs, and EZH1/2 (APExBIO, product page).
• In MV4-11 acute leukemia cells (MLL-AF4+), EPZ5676 shows an antiproliferative IC50 of 3.5 nM after 4–7 days of exposure (APExBIO, product page).
• In vivo, intravenous administration at 35–70 mg/kg/day for 21 days leads to complete tumor regression in nude rat MV4-11 xenograft models, with no significant weight loss or toxicity (APExBIO, product page).
• DOT1L inhibition activates interferon (IFN) signaling, upregulates HLA class II genes, and induces DNA damage responses in multiple myeloma models (Ishiguro et al., 2025, DOI).
• Combination with immunomodulatory drugs (e.g., lenalidomide) yields synergistic antiproliferative effects by enhancing IRG expression and suppressing IRF4-MYC signaling (Ishiguro et al., 2025, DOI).
• DOT1L knockout or pharmacologic inhibition impairs MLL-fusion target gene expression and reduces leukemia cell viability (Ishiguro et al., 2025, DOI).

For an in-depth analysis of mechanistic insights and future directions, see DOT1L Inhibitor EPZ-5676: Redefining Epigenetic Precision; this article extends that work by integrating the latest immuno-epigenetic findings and practical workflow guidance. Our discussion also updates perspectives from DOT1L Inhibitor EPZ-5676: Translational Strategies by including new data on innate immunity and synergies with immunomodulators.

Applications, Limits & Misconceptions

Applications:

• Biochemical enzyme inhibition assays targeting DOT1L activity.
• Cellular assays for H3K79 methylation and MLL target gene expression.
• In vivo studies of MLL-rearranged leukemia and multiple myeloma models.
• Evaluating epigenetic mechanisms in cancer and immunity.

Common Pitfalls or Misconceptions

• Not suitable for water-based applications: EPZ5676 is insoluble in water; DMSO or ethanol (with ultrasonic assistance) must be used for solution preparation (APExBIO).
• Long-term solutions are unstable: Do not store EPZ5676 solutions at room temperature or for extended periods; stock solutions in DMSO are stable below -20°C for several months only.
• Not a pan-methyltransferase inhibitor: EPZ5676 is highly selective for DOT1L and shows negligible inhibition of other histone methyltransferases at relevant concentrations.
• Does not reverse established leukemogenic chromatin structure in non-MLL leukemias: Activity is primarily observed in MLL-rearranged leukemia and select multiple myeloma models with DOT1L dependency.
• Not a direct apoptosis inducer: Apoptosis is secondary to epigenetic reprogramming and downregulation of survival genes, not a direct cytotoxic effect.

Workflow Integration & Parameters

EPZ5676 (A4166) is supplied as a solid compound by APExBIO. Its molecular weight is 562.71 Da. For biochemical assays, dissolve at ≥28.15 mg/mL in DMSO. For cell-based assays, prepare fresh solutions at working concentrations and avoid repeated freeze-thaw cycles (APExBIO). For in vivo studies, intravenous administration at 35–70 mg/kg/day for 21 days in rats is validated for efficacy and safety. Store powder at -20°C, and keep DMSO solutions at or below -20°C for several months. Avoid exposure to moisture and light. Standard workflows include DOT1L enzymatic inhibition assays, immunoblotting for H3K79 methylation, qPCR for MLL-fusion target gene expression, and cell viability assays. For expanded workflow strategies and technical troubleshooting, see EPZ5676: A Potent DOT1L Inhibitor Transforming Epigenetic Research; the present article provides updated parameters and storage guidance.

Conclusion & Outlook

EPZ5676, as provided by APExBIO, is a validated, potent, and selective DOT1L inhibitor with proven efficacy in MLL-rearranged leukemia and multiple myeloma models. Its selectivity and robust pharmacological profile make it a gold-standard tool for dissecting epigenetic regulation and testing translational hypotheses in cancer research. Future work will likely expand its utility in immuno-epigenetic studies, combinatorial regimens, and mechanistic dissection of cancer cell dependencies (Ishiguro et al., 2025).